Allena Pharmaceuticals Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allena Pharmaceuticals stock.
View analyst ratings for Allena Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Allena Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Allena Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Allena Pharmaceuticals saw a decline in short interest in the month of February. As of February 12th, there was short interest totaling 902,100 shares, a decline of 33.7% from the January 28th total of 1,360,000 shares. Based on an average daily volume of 2,370,000 shares, the days-to-cover ratio is currently 0.4 days.
View Allena Pharmaceuticals' Short Interest.

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Allena Pharmaceuticals.

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) announced its quarterly earnings results on Saturday, November, 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.01.
View Allena Pharmaceuticals' earnings history.

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALNA stock has increased by 34.1% and is now trading at $1.69.
View which stocks have been most impacted by COVID-19.

5 brokerages have issued 1 year price targets for Allena Pharmaceuticals' shares. Their forecasts range from $5.00 to $18.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $10.40 in the next year. This suggests a possible upside of 515.4% from the stock's current price.
View analysts' price targets for Allena Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Allena Pharmaceuticals include Applied Genetic Technologies (AGTC), INmune Bio (INMB), Gamida Cell (GMDA), ADMA Biologics (ADMA), Ayala Pharmaceuticals (AYLA), Axcella Health (AXLA), Voyager Therapeutics (VYGR), Genfit (GNFT), Pluristem Therapeutics (PSTI), Protara Therapeutics (TARA), Fennec Pharmaceuticals (FENC), Protalix BioTherapeutics (PLX), ERYTECH Pharma (ERYP), Idera Pharmaceuticals (IDRA) and Champions Oncology (CSBR).
View all of ALNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).

(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Allena Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Worth Venture Partners LLC (1.33%), Renaissance Technologies LLC (0.65%), BlackRock Inc. (0.43%) and Golden Green Inc. (0.10%). Company insiders that own Allena Pharmaceuticals stock include Edward Wholihan and Louis Md Brenner.
View institutional ownership trends for Allena Pharmaceuticals.

ALNA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Worth Venture Partners LLC, Golden Green Inc., and BlackRock Inc..
View insider buying and selling activity for Allena Pharmaceuticals or or view top insider-buying stocks.

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNA stock can currently be purchased for approximately $1.69.

Allena Pharmaceuticals has a market capitalization of $64.71 million. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

Allena Pharmaceuticals employs 32 workers across the globe.

The official website for Allena Pharmaceuticals is www.allenapharma.com.

Allena Pharmaceuticals is headquartered at ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462.

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.